Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer : a multicenter retrospective study
2022 Translational Lung Cancer Research. All rights reserved..
Background: Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the impact of different types of topoisomerase inhibitors for first-line chemotherapy on the efficacy of amrubicin remains unclear. In the present study, we aimed to evaluate the efficacy of second-line amrubicin in patients with relapsed SCLC who were previously treated with platinum-based chemotherapy, including topoisomerase I and II inhibitors.
Methods: This study retrospectively analyzed patients with ES-SCLC who experienced recurrence and were treated with amrubicin at 22 institutions in Japan between April 2015 and November 2020. The progression-free survival of amrubicin monotherapy was investigated using the Kaplan-Meier method.
Results: A total of 320 patients were enrolled in this study, with 59 (18%) receiving platinum plus topoisomerase I inhibitor irinotecan and 261 (82%) receiving platinum plus topoisomerase II inhibitor etoposide as first-line treatment. The progression-free survival of amrubicin was significantly longer in the irinotecan group than in the etoposide group (3.2 vs. 2.5 months; P=0.034).
Conclusions: These results showed that different types of topoisomerase inhibitors could affect the efficacy of amrubicin monotherapy in the second-line treatment of patients with relapsed ES-SCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Translational lung cancer research - 11(2022), 9 vom: 13. Sept., Seite 1847-1857 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Uda, Sayaka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amrubicin |
|---|
| Anmerkungen: |
Date Revised 19.10.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/tlcr-22-160 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347632939 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347632939 | ||
| 003 | DE-627 | ||
| 005 | 20231226034306.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/tlcr-22-160 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347632939 | ||
| 035 | |a (NLM)36248326 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Uda, Sayaka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer |b a multicenter retrospective study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2022 Translational Lung Cancer Research. All rights reserved. | ||
| 520 | |a Background: Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the impact of different types of topoisomerase inhibitors for first-line chemotherapy on the efficacy of amrubicin remains unclear. In the present study, we aimed to evaluate the efficacy of second-line amrubicin in patients with relapsed SCLC who were previously treated with platinum-based chemotherapy, including topoisomerase I and II inhibitors | ||
| 520 | |a Methods: This study retrospectively analyzed patients with ES-SCLC who experienced recurrence and were treated with amrubicin at 22 institutions in Japan between April 2015 and November 2020. The progression-free survival of amrubicin monotherapy was investigated using the Kaplan-Meier method | ||
| 520 | |a Results: A total of 320 patients were enrolled in this study, with 59 (18%) receiving platinum plus topoisomerase I inhibitor irinotecan and 261 (82%) receiving platinum plus topoisomerase II inhibitor etoposide as first-line treatment. The progression-free survival of amrubicin was significantly longer in the irinotecan group than in the etoposide group (3.2 vs. 2.5 months; P=0.034) | ||
| 520 | |a Conclusions: These results showed that different types of topoisomerase inhibitors could affect the efficacy of amrubicin monotherapy in the second-line treatment of patients with relapsed ES-SCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Small cell lung cancer (SCLC) | |
| 650 | 4 | |a amrubicin | |
| 650 | 4 | |a etoposide | |
| 650 | 4 | |a irinotecan | |
| 650 | 4 | |a topoisomerase inhibitor | |
| 700 | 1 | |a Yamada, Tadaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimura, Akihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Goto, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimine, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Yoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Shiotsu, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yokoi, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Tamiya, Nobuyo |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Hideharu |e verfasserin |4 aut | |
| 700 | 1 | |a Chihara, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Umeda, Yukihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Miiru |e verfasserin |4 aut | |
| 700 | 1 | |a Takeda, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hibino, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Hiranuma, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Asuka |e verfasserin |4 aut | |
| 700 | 1 | |a Osugi, Shuji |e verfasserin |4 aut | |
| 700 | 1 | |a Takemura, Yoshizumi |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Chibana, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Isao |e verfasserin |4 aut | |
| 700 | 1 | |a Morimoto, Yoshie |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaku, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tokuda, Shinsaku |e verfasserin |4 aut | |
| 700 | 1 | |a Takayama, Koichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational lung cancer research |d 2012 |g 11(2022), 9 vom: 13. Sept., Seite 1847-1857 |w (DE-627)NLM24739839X |x 2218-6751 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:9 |g day:13 |g month:09 |g pages:1847-1857 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/tlcr-22-160 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 9 |b 13 |c 09 |h 1847-1857 | ||